https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=13624

Cobicistat

Vardenafil

Dosage adjustment is recommended.

No pharmaceutical opinion available for this interaction.

Mechanism

Cobicistat can decrease the metabolism (CYP3A4) and increase the plasma concentration of Vardenafil.

Cobicistat

Pharmacodynamic effects

–

Recommendations

–

Alternative solution(s)

–

Vardenafil

Pharmacodynamic effects

Possible increase of adverse effects.

Recommendations

Use this combination with caution.

Use a single maximum dose of vardenafil of 2.5 mg every 72 hours according to the US product monograph.

Monitor closely for adverse effects.

The canadian monograph contraindicates this combination.

Alternative solution(s)

See sildenafil and tadalafil.

Monitor

Vardenafil toxicity: hypotension, tachycardia, headache, dizziness, flushing, visual changes (difficulty distinguishing blue and green) and syncope.

Tests

–

Pharmacokinetic parameters

–

Comment

The monographs of vardenafil and ritonavir contraindicate the coadministration with a potent CYP 3A4 inhibitor.

Ref #1384 : Indeed, vardenafil AUC has increased by 49-fold when using a 5 mg vardenafil dose associated with ritonavir 600 mg BID, a potent inhibitor of cytochrome 3A4.

Caution:
- Liver impairment (Child Pugh B) : increases AUC to 160% and
- kidney failure (Clcr < 30 ml/min) : increases AUC to 20-30% and
- age > 65 years old : increases 52% of AUC.

See ritonavir and vardenafil.

Reference
  • 2949
    Cobicistat (Tybost), European public assessment report (EPAR) Product Information, London, United Kingdom, 4 juin 2015.
  • 3390
    Vardenafil (Levitra), Bayer Healthcare, New Jersey, USA, april 2014.
  • 1384
    Vardenafil (Levitra), Bayer, Ontario, Canada, 4 juin 2016.